By: IPP Bureau
Last updated : August 17, 2025 6:05 pm
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Xspray Pharma announced its first out-licensing agreement from its patent portfolio, signing a deal with Handa Therapeutics under which it will receive up to double-digit royalties on Handa’s net proceeds.
The company’s core strategy to develop and commercialize improved PKI drugs using its patented HyNap technology remains unchanged. Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025. Additional licensing agreements may be considered selectively.
“The agreement confirms the value of our patent portfolio and demonstrates that our long-term work to build our comprehensive patent portfolio is paying off. As for the dasatinib market, I’m convinced that when Dasynoc is launched it will be seen as the premium product in its market segment as it combines pH-independent absorption with lower dose strength and high precision, eliminating sensitivity to all acid-reducing agents,” says Per Andersson, CEO of Xspray Pharma.
The agreement also ensures that Xspray’s planned Dasynoc launch will not be impacted by any U.S. regulatory exclusivities related to Handa’s product, which has not yet been launched.